You can buy or sell SUPN and other stocks, options, ETFs, and crypto commission-free!
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. Read More The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
52 Week High
52 Week Low
Simply Wall StMar 15
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Is It A Smart Long Term Opportunity?
As Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings announcement on 31 December 2018, analysts seem cautiously bearish, with earnings expected to grow by 15% in the upcoming year compared with the higher past 5-year average growth rate of 64%. Currently with trailing-twelve-month earnings of US$111m, we can expect this to reach US$127m by 2020. Below is a brief commentary on the longer term outlook the market has for Supernus Pharmaceuticals. Investors wanting to learn more about other asp...
Long or Short: Supernus Pharmaceuticals (NASDAQ: SUPN)
Supernus Pharmaceuticals trades as part of the healthcare sector and is part of the drug manufacturers industry. The company CEO is Jack Khattar. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Previous Intraday Trading Performance: The SUPN stock showed a previous change of -0.43% with an open at 37.59 and a close of ...
Stock Price, News, & Analysis for Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial ...
Expected May 7, After Hours